Published in Oncotarget on October 04, 2016
A cellular platform for the evaluation of immune checkpoint molecules. Oncotarget (2017) 0.75
The Protein Data Bank. Nucleic Acids Res (2000) 187.10
The Amber biomolecular simulation programs. J Comput Chem (2005) 28.84
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Cancer immunotherapy comes of age. Nature (2011) 12.35
PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49
A hot spot of binding energy in a hormone-receptor interface. Science (1995) 10.41
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J (1992) 8.86
Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol (2008) 8.17
ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol (2011) 7.33
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 6.44
The FoldX web server: an online force field. Nucleic Acids Res (2005) 6.30
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24
Unraveling hot spots in binding interfaces: progress and challenges. Curr Opin Struct Biol (2002) 6.06
Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78
The backrub motion: how protein backbone shrugs when a sidechain dances. Structure (2006) 5.71
The future of immune checkpoint therapy. Science (2015) 5.59
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
Computational alanine scanning of protein-protein interfaces. Sci STKE (2004) 3.41
Sub-angstrom accuracy in protein loop reconstruction by robotics-inspired conformational sampling. Nat Methods (2009) 3.25
Synthetic therapeutic peptides: science and market. Drug Discov Today (2009) 2.95
PD-1 and its ligands in T-cell immunity. Curr Opin Immunol (2007) 2.86
ASEdb: a database of alanine mutations and their effects on the free energy of binding in protein interactions. Bioinformatics (2001) 2.60
Practically useful: what the Rosetta protein modeling suite can do for you. Biochemistry (2010) 2.56
Peptide therapeutics: current status and future directions. Drug Discov Today (2014) 1.83
Identification of computational hot spots in protein interfaces: combining solvent accessibility and inter-residue potentials improves the accuracy. Bioinformatics (2009) 1.80
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med (2014) 1.59
PD-1/PD-L1 inhibitors. Curr Opin Pharmacol (2015) 1.53
KFC2: a knowledge-based hot spot prediction method based on interface solvation, atomic density, and plasticity features. Proteins (2011) 1.38
Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol (2014) 1.29
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. Structure (2015) 1.27
Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol (2015) 1.21
Relaxation of backbone bond geometry improves protein energy landscape modeling. Protein Sci (2014) 1.19
A mutational analysis of the binding of two different proteins to the same antibody. Biochemistry (1996) 1.18
PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget (2015) 1.02
Cancer immunology and immunotherapy. Realizing the promise. Introduction. Science (2015) 1.00
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. Oncotarget (2015) 0.99
Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget (2016) 0.92
A new scoring function and associated statistical significance for structure alignment by CE. J Comput Biol (2004) 0.88
Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy. Angew Chem Int Ed Engl (2015) 0.88
Modulating protein-protein interactions: from structural determinants of binding to druggability prediction to application. Curr Pharm Des (2012) 0.84
PredHS: a web server for predicting protein-protein interaction hot spots by using structural neighborhood properties. Nucleic Acids Res (2014) 0.80